Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.

Old Articles: <Older 19961-19970 Newer>

The Motley Fool January 22, 2007 Brian Lawler	Another Busy Year in Store for Novartis Trying to place a value on Novartis is a tough thing to do now with so many important drugs awaiting regulatory review and its addiction to acquisitions and divestitures making financial comparisons between the years tough.
The Motley Fool January 22, 2007 Rich Smith	Foolish Forecast: A Few ChoicePoints The the data collector, collator, and disseminator is set to report its fourth-quarter and full-year 2006 results. Investors, here's what to expect.
The Motley Fool January 22, 2007 Rich Smith	Foolish Forecast: General Dynamics on Deck The the defense contractor is set to report its fourth-quarter and full-year 2006 earnings results. Investors, here's what to expect.
The Motley Fool January 22, 2007 Michael P. Cecil	Will Medicare Negotiate With Drug Companies? One of the bedrock principles of our economic system is that those buying more of a product receive a discount. Wouldn't empowering Medicare to save taxpayers' money be widely embraced as a great idea? But how would pharma investors see it?
The Motley Fool January 22, 2007 Tim Beyers	Anatomy of a Multibagger: Akamai Technologies How do you quadruple your money in two years? Investors, don't speculate. Seek leaders with obvious and identifiable advantages and the capital to exploit them effectively.
The Motley Fool January 22, 2007 David Lee Smith	The Times, It Is A-Marketing The New York Times gets the word out to boost sales. But will the new campaign really change the company's fortunes much? Investors, take note.
The Motley Fool January 22, 2007 Rich Smith	Foolish Forecast: 1-800-Flowers Calls It Good The flower hawker is set to report its fiscal second-quarter 2007 earnings report. Investors, here's what to expect.
The Motley Fool January 22, 2007 Emil Lee	Suntrust to Take Scalpel to Expenses Suntrust outlines a new $400 million cost-cutting goal. Is it music to shareholders' ears?
The Motley Fool January 22, 2007 Tom Taulli	Cognos: Dipping Into On-Demand The traditional enterprise software developer is pushing into online delivery. Investors, the prospects for Cognos look promising in 2007.
The Motley Fool January 22, 2007 Brian Lawler	Adios, ICOS The pharmaceutical gets finally consumed by Eli Lilly. The deal offered a nice premium to ICOS shareholders. At the same time, it was a good deal for Lilly.
<Older 19961-19970 Newer> Return to current articles.